The European electronic lab notebooks (ELN) market is the scene of much change today as the technology continues to develop rapidly and become more refined with each passing day. Surpassing the capabilities of traditional bound laboratory notebooks, ELNs provide a sophisticated communications platform that enables researchers to share experiment-related information seamlessly, and even improve or reuse the data. It also satisfies multiple intellectual property and regulatory requirements, allowing significant reductions in cycle times in biopharmaceutical R&D.
“Frost & Sullivan expects to see continued and rapid growth from the specific ELN segment,” notes Frost & Sullivan Programme Leader of Drug Discovery Dr. Amarpreet Dhiman. “One of the key advances in ELN technology has been the ability to cater to niche end users with specific solutions that include features such as authentication, sign/witness, audit, notebook record repository and reporting services with extensive workflow customisation capabilities.”
New analysis from Frost & Sullivan (healthcareandlifesciencesIT.frost.com), European Electronic Lab Notebooks (ELN) Markets, reveals that these markets earned revenues of $32.3 million in 2006 and estimates this to reach $143.1 million in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of European Electronic Lab Notebooks (ELN) Markets, then send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore[.]frost.com with your full name, company name, title, telephone number, fax number and email address. Upon receipt of the above information, an overview will be sent to you by email.
Pharmaceuticals and biotechnology companies can now deploy an ELN platform across their entire R&D processes and gain dramatic improvements in productivity, collaboration and regulatory compliance. Although ELNs are by no means the only knowledge system in the drug development and life sciences chain, they are definitely a key link in the chain that allows end users to capture and share all the unique and proprietary information they generate.
However, many organisations are concerned about ELN affecting their processes and ways of working and this has impacted ELN adoption. The extent of changes that scientists would have to make if they invested in ELNs is considerable, and could range from training staff and adopting new processes to upgrading other systems to make them compatible with ELN. This is bound to lead to some amount of resistance from scientists, particularly since the traditional paper lab notebook has dominated the scientific environment for so many years.
“ELNs represent a potential solution for meeting the need of companies to protect their intellectual property and the needs of end users,” says Dr. Dhiman. “However, before they can be adopted by companies as the principal method of recording lab data, they must meet the reliability, authenticity and corroboration criteria established for paper laboratory notebooks.”
Security is a particularly important aspect of the ELN database, especially when entering and updating data in the ELN platform. The challenge is to maintain an audit trail during such updates and to provide suitable IT administration features to ensure effective and secure running of the system.
ELNs also need to have a high degree of flexibility that allows scientists from different disciplines to continue working in ways that best suit their needs. They need to be sufficiently structured to enable an ordered and managed approach to record-keeping and must also offer advanced search capabilities.
“Scientific requirements need to be appropriately articulated so that ELNs satisfy and accommodate the needs of all labs while simultaneously working more efficiently and effectively,” concludes Dr. Dhiman. “The European ELN market is expected to continue to grow rapidly over the next several years as ELNs move into the mainstream and developers continue to release application-specific solutions as well as develop a host of interfaces for other add-ons fulfilling end-user demands.”
European Electronic Lab Notebooks (ELN) Markets is part of the Healthcare and Life Sciences IT Growth Partnership Service program, which also includes research in the following: Virtual Screening Opportunities in Drug Discovery in Europe, European Bioinformatics Markets, and Data Integration in Life Science Companies. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.